Study: Perera 2013, Lancet

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

Citation

Perera MA, Cavallari LH, Limdi NA, Gamazon ER et al (2013). Lancet. PubMed id 23755828.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • How some medicines work differently by gene Tier B moderate

    B 533 African American adults on stable warfarin (discovery) and 432 (replication) (n=965)

    Genome-wide association study.

    VKORC1 and CYP2C9 explain less dose variation in people of African descent than in Europeans or Asians. A novel variant in the CYP2C cluster (rs12777823) reached genome-wide significance in the discovery cohort and was confirmed in the replication cohort.

    As recorded in this card: Perera MA, Cavallari LH, Limdi NA, Gamazon ER et al (2013), Lancet, [primary]

    Note: African American adults; a genetic association, not a trial. The abstract was cut before the effect size on dose.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.